The abstract reveals that DPP-4 inhibitors reduce Alzheimer's pathology yet worsen cardiovascular outcomes via increased sympathetic activity. This mechanistic contradiction within the heart-brain axis is unexplained and critical for therapeutic decision-making in diabetic patients. Gap type: contradiction Source paper: Interactions between antidiabetes medications and heart-brain axis. (2025, Current opinion in endocrinology, diabetes, and obesity, PMID:39639832)
Landscape Summary: Why do DPP-4 inhibitors show neuroprotective effects but increase heart failure risk through sympathetic activation? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why do DPP-4 inhibitors show neuroprotective effects but increase heart failure risk through sympathetic activation? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: